Trinity Delta Lighthouse: Avacta
Trinity Delta view: The potential for long-term value creation in both Avacta divisions is highlighted by: (1) clinical momentum in Therapeutics as lead pre|CISION asset AVA6000 approaches key data read out and initiation of the first potentially registrational trial; and (2) by the commercial momentum in the maturing Diagnostics business as it advances towards self-sustainability. Avacta’s near- and medium-term Therapeutics prospects are underpinned by the pre|CISION platform, with AVA6000 data helping to validate the platform’s tumour targeting potential and providing the blueprint for a pipeline of related products, such as AVA3996. Accelerated clinical development for AVA6000 could mean approval of the first pre|CISION targeted chemotherapy towards end-2026. Our current Avacta valuation is £641m (equivalent to 228p per share).Avacta Group is a biotechnology company that is developing biotherapeutics and reagents based on its proprietary Affimer technology, an engineered alternative to antibodies. Affimer® reagents and therapeutics are a class of non-antibody binding proteins that have been engineered for a range of applications where antibodies and aptamers have limitations. Co. has two operating segments: Life Sciences, which provides custom Affimers for reagents and diagnostics, drug and biomarker discovery in biotech research and development; and Animal Health, which provides tools and contract services to assist diagnosis of conditions in animals to enable treatment for veterinarians.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.